Mostrar el registro sencillo del ítem
Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines
| dc.rights.license | open | en_US |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | COUZI, Lionel | |
| dc.contributor.author | MALVEZZI, P. | |
| dc.contributor.author | AMROUCHE, L. | |
| dc.contributor.author | ANGLICHEAU, D. | |
| dc.contributor.author | BLANCHO, G. | |
| dc.contributor.author | CAILLARD, S. | |
| dc.contributor.author | FREIST, M. | |
| dc.contributor.author | GUIDICELLI, G.L. | |
| dc.contributor.author | KAMAR, N. | |
| dc.contributor.author | LEFAUCHEUR, C. | |
| dc.contributor.author | MARIAT, C. | |
| dc.contributor.author | KOENIG, A. | |
| dc.contributor.author | NOBLE, J. | |
| dc.contributor.author | THAUNAT, O. | |
| dc.contributor.author | THIERRY, A. | |
| dc.contributor.author | TAUPIN, J.-L. | |
| dc.contributor.author | BERTRAND, D. | |
| dc.date.accessioned | 2024-09-25T10:36:17Z | |
| dc.date.available | 2024-09-25T10:36:17Z | |
| dc.date.issued | 2023 | |
| dc.identifier.issn | 0934-0874 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/201799 | |
| dc.description.abstractEn | Imlifidase recently received early access authorization for highly sensitized adult kidney transplant candidates with a positive crossmatch against an ABO-compatible deceased donor. These French consensus guidelines have been generated by an expert working group, in order to homogenize patient selection, associated treatments and follow-up. This initiative is part of an international effort to analyze properly the benefits and tolerance of this new costly treatment in real-life. Eligible patients must meet the following screening criteria: cPRA ≥ 98%, ≤ 65-year of age, ≥ 3 years on the waiting list, and a low risk of biopsy-related complications. The final decision to use Imlifidase will be based on the two following criteria. First, the results of a virtual crossmatch on recent serum, which shall show a MFI for the immunodominant donor-specific antibodies (DSA) > 6,000 but the value of which does not exceed 5,000 after 1:10 dilution. Second, the post-Imlifidase complement-dependent cytotoxicity crossmatch must be negative. Patients treated with Imlifidase will receive an immunosuppressive regimen based on steroids, rATG, high dose IVIg, rituximab, tacrolimus and mycophenolic acid. Frequent post-transplant testing for DSA and systematic surveillance kidney biopsies are highly recommended to monitor post-transplant DSA rebound and subclinical rejection. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Kidney transplantation | |
| dc.subject.en | Desensitization | |
| dc.subject.en | Imlifidase | |
| dc.subject.en | Highly sensitized patients | |
| dc.subject.en | Positive crossmatch | |
| dc.title.en | Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3389/ti.2023.11244 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| dc.identifier.pubmed | 37448448 | en_US |
| bordeaux.journal | Transplant International | en_US |
| bordeaux.volume | 36 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04709070 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-09-25T10:36:20Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | CC BY | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Transplant%20International&rft.date=2023&rft.volume=36&rft.eissn=0934-0874&rft.issn=0934-0874&rft.au=COUZI,%20Lionel&MALVEZZI,%20P.&AMROUCHE,%20L.&ANGLICHEAU,%20D.&BLANCHO,%20G.&rft.genre=article |
